The European Food Safety Authority (EFSA) will publish a sixth and final ‘mini-batch’ of Article 13.1 health claims opinions at the end of July.
The batch will contain five opinions on 35 claims relating to ingredients including creatine and soy isoflavones.
It will bring to 2,758 the number of claims assessed by EFSA under the Article 13.1 process, which is reserved for general function claims that will form the basis of a Community List of approved claims that can be used by anyone.
On June 30, EFSA published its fifth batch, containing 73 opinions covering 536 claims. Once more, there were no positive opinions for probiotics.
But there were favorable outcomes for claims relating to dietary fibers and blood cholesterol; cereal fiber and bowel function; carbohydrate-electrolyte drinks and endurance performance; low sodium and blood pressure; dietary fiber and reduced increase in blood glucose after meals; melatonin and sleep onset; and a a very low calorie diet in relation to body weight.
Although the publication of this month’s mini-batch will be a major milestone in the implementation of the health claims regulation, uncertainty persists over the fate of 1,548 claims relating to botanicals.
These have been put on hold by the Commission, which was concerned that the way such ingredients are treated under the health claims regulation is at odds with their treatment under the EU Directive on Traditional Herbal Medicinal Products.